Bedrijfsoverzicht
Biohaven Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, and commercialization of novel treatments across the therapeutic areas of immunology, neuroscience, and oncology on a global scale. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, a classification that signifies a focus on innovative drug development rather than mature manufacturing or service provision. Its current operational scale is reflected in a market capitalization of $1.38B and a workforce comprising 274 employees, figures that position the entity as a mid-cap player with significant resource requirements typical of late-stage clinical development phases. The absence of reported annual revenue in the available data suggests that the company is likely still generating income primarily through financing or licensing rather than substantial commercial sales, a common characteristic for biotechnology firms where significant capital is allocated to research and clinical trials before achieving widespread market penetration.
Financiële gezondheid
The financial statements for Biohaven Ltd. report a Net Income (TTM) of $-738,822,016 and an EBITDA of $-698,445,120, while the Revenue (TTM) is listed as N/A, indicating that the gap between nominal revenue and substantial net losses is driven by high operating costs inherent in clinical research rather than inefficient cost management relative to sales volume. The company reports a Free Cash Flow of $-358,118,432, which signifies a continuous burn rate that limits immediate financial flexibility and necessitates a reliance on external capital markets to fund ongoing operations and trial expenses. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that in this context reflects the company's developmental stage where revenue is either negligible or insufficient to cover the massive fixed costs of drug development, resulting in zero profitability on sales. The balance sheet shows a Cash position of $319.14M against a Debt obligation of $284.61M, creating a leverage profile quantified by a Debt to Equity ratio of 546.58, which indicates a highly leveraged structure reliant on equity financing rather than debt repayment given the negative earnings. Liquidity is supported by a Current Ratio of 3.18, suggesting the company holds sufficient current assets to cover its short-term liabilities multiple times over, providing a buffer against immediate solvency risks despite the negative earnings. Return on Equity stands at -310.8% and Return on Assets is -83.0%, metrics that reveal management is currently utilizing shareholder capital and assets to generate significant losses rather than returns, a typical but risky profile for companies in the early commercialization phase of their pipeline assets like BHV-1300.
Waarderingsbeoordeling
Valuation metrics for Biohaven Ltd. present a complex picture, with a Forward P/E of -4.70 and a Trailing P/E (TTM) listed as N/A due to the lack of positive earnings, implying that traditional price-to-earnings multiples are not applicable until the company transitions to profitability. The Price to Book ratio is 23.39, a figure that indicates the market values the company's equity at a substantial premium relative to its book value, reflecting high expectations for the future success of its drug candidates despite current financial losses. Alternative valuation indicators such as Price to Sales (N/A) and EV/EBITDA (-1.93) further highlight the speculative nature of the stock, where the negative EV/EBITDA confirms that the enterprise value is not supported by current earnings generation but rather by asset potential and pipeline value. Price action over the last year shows a 52-Week High of $24.06 and a 52-Week Low of $7.48, with the current trading environment requiring calculation of the exact percentage distance from these bounds to determine relative positioning within the recent volatility range. The stock exhibits a Beta of 3.62, meaning that price fluctuations are expected to be more than three and a half times the magnitude of movements in the broader market, signaling extreme sensitivity to market sentiment and sector-specific news regarding clinical trial results.
Growth & Income
Biohaven Ltd. reports N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), which prevents a direct comparison of growth rates between earnings and revenue as both are currently undefined or negligible in the provided data. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating a corporate strategy that prioritizes the reinvestment of all available cash flow into research, development, and clinical trials rather than income generation for investors. The absence of dividend payments and the presence of significant negative Free Cash Flow confirm that the company's primary growth mechanism is the advancement of its therapeutic pipeline rather than financial engineering or shareholder returns. The overall growth and income profile is characterized by high risk and high capital intensity, where value accrual is entirely dependent on the successful commercialization of future products like BHV-1300 for Graves' disease and rheumatoid arthritis rather than current operational profitability.